Objective In this study, we aimed to compare the severity and outcomes in 
hypertensive patients presenting with coronavirus disease 2019 (COVID-19) who 
were taking angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin 
receptor blockers (ARBs) and those who were on other antihypertensive drugs. 
Methods This retrospective cohort study involved 182 hypertensive patients who 
presented with COVID-19 infection. The study population comprised 91 patients 
who were taking ACEIs/ARBs (group A) and 91 patients who were taking other 
antihypertensive drugs such as β-blockers (BBs), calcium channel blockers 
(CCBs), or thiazides (group B). All patients were provided the same type of 
treatment for the management of COVID-19. We recorded the data related to 
demographic and anthropometric variables as well as clinical symptoms during the 
treatment period. Disease severity and hospital mortality were the primary study 
endpoints. Results There was no significant difference in COVID-19-related 
outcomes between the groups except for the severity of lung infiltration on 
chest X-rays. There were 37 (41.1%) patients having >50% lung infiltration in 
group A and 53 (58.2%) in group B (p-value: 0.02). Severe disease was diagnosed 
in 37 (40.7%) patients in group A compared to 39 (42.7%) patients in group B 
(p-value: 0.76). In-hospital mortality was noted in 17 (18.7%) patients in group 
A and 22 (24.2%) patients in group B (p-value: 0.36). Conclusion Based on our 
results, we did not find any significant association between the use of 
ACEIs/ARBs and either the severity of COVID-19 infection necessitating admission 
to ICU or in-hospital mortality.